GLYC - GlycoMimetics Stock Trading
News, Short Squeeze, Breakout and More Instantly...
-
Manuscript highlights MRD negative rate of 69% in the relapsed/refractory patient population Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics’ lead investigational drug, were published online September 16, 2021 in the journal BL...
-
Image source: The Motley Fool. GlycoMimetics, inc (NASDAQ: GLYC) Q2 2021 Earnings Call Aug 6, 2021 , 2:00 p.m. ET Operator Continue reading For further details see: GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript
-
Completion of enrollment is expected by year-end 2021 for the Company-sponsored Phase 3 pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Completion of enrollment is expected by year-end 2021 for the Phase 2 portion of the...